Loss of Exclusivity (LOE)

The year a drug’s patent and regulatory protection ends and generic or biosimilar competition arrives. Revenue typically falls to a fraction of its peak within a year or two for small molecules, more slowly for biologics. In a valuation it truncates the programme’s cash flows, and moving it by a year or two is one of the most sensitive changes a model can take.

Where Loss of Exclusivity (LOE) comes up

Biotech Valuation: rNPV, Launch Curves and the Sum of the PartsA company with no earnings is valued on what its pipeline would earn if it worked, weighted by the chance that it does.Read the guide — 12 min

Keep reading

Biotech rNPV valuation guide

Related Healthcare terms

Peak Sales Probability of Technical and Regulatory Success (PTRS)Gross-to-Net rNPV (Risk-Adjusted Net Present Value)

Go further than reading

The written material is free. These are the ways to get it applied to your own work.

CV Review by a Human

Written margin-note feedback on structure, impact bullets and ATS-readability. Reviewed by Suro, not an AI score.

$25 48h turnaround

Cover Letter Review by a Human

Line-by-line review of argument, tailoring and tone, with a rewritten opening as a worked example.

$50 48h turnaround

L3VLUP Pro

The subscription: personalised alerts, Apply Packs, every answer marked, full history and the whole research library.

$25 /month

Browse the full glossary — 293 finance recruiting and technical terms, in plain English.